Start Date
February 29, 2016
Primary Completion Date
July 31, 2017
Study Completion Date
November 30, 2017
NK-104-CR
NK-104-CR 8 mg for 52 weeks
Livalo® IR
Livalo® IR 4 mg daily for 52 weeks
Placebo (for NK-104-CR)
NK-104-CR 8 mg placebo for 52 weeks
Placebo (for Livalo® IR)
Livalo® IR 4 mg placebo for 52 weeks
Foley
Huntsville
Montgomery
Muscle Shoals
Little Rock
Greenbrae
Huntington Park
Lomita
Long Beach
Los Angeles
Santa Ana
Spring Valley
Tustin
Walnut Creek
Milford
Atlantis
Cooper City
Coral Springs
Fleming Island
Jacksonville
Miami
Oviedo
Dawsonville
Macon
Suwanee
Addison
Chicago
Gurnee
Morton
Evansville
Topeka
Louisville
Owensboro
Oxon Hill
Biloxi
Olive Branch
Jefferson City
St Louis
Omaha
Manlius
High Point
Salisbury
Wilmington
Winston-Salem
Fargo
Cincinnati
Columbus
Franklin
Oklahoma City
Medford
Beaver
Harleysville
Jersey Shore
Philadelphia
Pittsburgh
Moncks Corner
Simpsonville
Summerville
Austin
Houston
Katy
Plano
Round Rock
San Antonio
Salt Lake City
Richmond
Suffolk
Seattle
Kenosha
Lead Sponsor
Kowa Research Institute, Inc.
INDUSTRY